• MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

  Kufe DW.
  Carcinogenesis. 2020 Sep 24. 9(41).

• Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.

  Dannenfelser R, Allen GM, VanderSluis B, Koegel AK, Levinson S, Stark SR, Yao V, Tadych A, Troyanskaya OG, Lim WA.
  Cell Syst. 2020 Sep 23. 3(11).

• The Promise of Combining Radiation Therapy With Immunotherapy.

  Jagodinsky JC, Harari PM, Morris ZS.
  Int J Radiat Oncol Biol Phys. 2020 Sep 01. 1(108).

• Inhibition of LSD1 in MDS progenitors restores differentiation of CD141^Hi conventional dendritic cells.

  Srivastava P, Tzetzo SL, Gomez EC, Eng KH, Jani Sait SN, Kuechle JB, Singh PK, De Jong K, Wiatrowski KR, Peresie J, Dimitroff A, Lynch ML, Wang J, Abrams SI, Griffiths EA, Nemeth MJ.
  Leukemia. 2020 Sep. 9(34).

• BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.

  Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, Costich TL, Harro CM, Walrath J, Ming Q, Tcyganov E, Buras AL, Rigolizzo KE, Mandal G, Lajoie J, Ophir M, Tchou J, Marchion D, Luca VC, Bobrowicz P, McLaughlin B, Eskiocak U, Schmidt M, Cubillos-Ruiz JR, Rodriguez PC, Gabrilovich DI, Conejo-Garcia JR.
  Science. 2020 Aug 21. 6506(369).
  
  Model

• Unleashing Immunotherapy by Targeting Cancer Stem Cells.

  Iglesias-Bartolome R, Gutkind JS.
  Cell Stem Cell. 2020 Aug 06. 2(27).

• CoMut: visualizing integrated molecular information with comutation plots.

  Crowdis J, He MX, Reardon B, Van Allen EM.
  Bioinformatics. 2020 Aug 01. 15(36).

• ¹⁷⁷Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer.

  Hernandez R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, Pinchuk AN, Bitton AN, Patel R, Zhang R, Rao AV, Iyer G, Engle JW, Weichert JP.
  J Nucl Med. 2020 Aug. 8(61).

• Old dogs, new trick: classic cancer therapies activate cGAS.

  Yum S, Li M, Chen ZJ.
  Cell Res. 2020 Aug. 8(30).

• Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples.

  Panda A, Yadav A, Yeerna H, Singh A, Biehl M, Lux M, Schulz A, Klecha T, Doniach S, Khiabanian H, Ganesan S, Tamayo P, Bhanot G.
  Nucleic Acids Res. 2020 Jul 27. 13(48).

• The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis.

  Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gillilland MG, Hayashi A, Imai J, Sugihara K, Miyoshi M, Brazil JC, Kuffa P, Hill BD, Rizvi SM, Wen F, Bishu S, Inohara N, Eaton KA, Nusrat A, Lei YL, Giannobile WV, Kamada N.
  Cell. 2020 Jul 23. 2(182).

• A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.

  Castellarin M, Sands C, Da T, Scholler J, Graham K, Buza E, Fraietta JA, Zhao Y, June CH.
  JCI Insight. 2020 Jul 23. 14(5).
  
  Model

• Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway.

  Zhang X, Bai XC, Chen ZJ.
  Immunity. 2020 Jul 14. 1(53).

• A Sectioning and Database Enrichment Approach for Improved Peptide Spectrum Matching in Large, Genome-Guided Protein Sequence Databases.

  Kumar P, Johnson JE, Easterly C, Mehta S, Sajulga R, Nunn B, Jagtap PD, Griffin TJ.
  J Proteome Res. 2020 Jul 02. 7(19).

• Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

  Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, Horowitz MM, Riches ML, Hematti P, Turtle CJ, Zhang MJ, Perales MA, Pasquini MC.
  Blood. 2020 Jul 02. 1(136).

• RBCs prevent rapid PIEZO1 inactivation and expose slow deactivation as a mechanism of dehydrated hereditary stomatocytosis.

  Evans EL, Povstyan OV, De Vecchis D, Macrae F, Lichtenstein L, Futers TS, Parsonage G, Humphreys NE, Adamson A, Kalli AC, Ludlow MJ, Beech DJ.
  Blood. 2020 Jul 02. 1(136).

• Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy.

  Hai J, Zhang H, Zhou J, Wu Z, Chen T, Papadopoulos E, Dowling CM, Pyon V, Pan Y, Liu JB, Bronson RT, Silver H, Lizotte PH, Deng J, Campbell JD, Sholl LM, Ng C, Tsao MS, Thakurdin C, Bass AJ, Wong KK.
  Clin Cancer Res. 2020 Jul 01. 13(26).
  
  Model

• B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.

  Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi AB.
  Clin Cancer Res. 2020 Jul 01. 13(26).

• IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.

  Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM.
  Nature. 2020 Jul. 7817(583).
  
  Data Model

• Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice.

  Eguchi A, Yan R, Pan SQ, Wu R, Kim J, Chen Y, Ansong C, Smith RD, Tempaku M, Ohno-Machado L, Takei Y, Feldstein AE, Tsukamoto H.
  J Mol Med (Berl). 2020 Jul. 7(98).

• In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.

  Clark PA, Sriramaneni RN, Jin WJ, Jagodinsky JC, Bates AM, Jaquish AA, Anderson BR, Le T, Lubin JA, Chakravarty I, Arthur IS, Heinze CM, Guy EI, Kler J, Klar KA, Carlson PM, Kim KM, Kuo JS, Morris ZS.
  J Immunother Cancer. 2020 Jul. 2(8).

• Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response.

  Dhanwani R, Takahashi M, Mathews IT, Lenzi C, Romanov A, Watrous JD, Pieters B, Hedrick CC, Benedict CA, Linden J, Nilsson R, Jain M, Sharma S.
  Sci Adv. 2020 Jul. 30(6).
  
  Data

• Detection of response to tumor microenvironment-targeted cellular immunotherapy using nano-radiomics.

  Devkota L, Starosolski Z, Rivas CH, Stupin I, Annapragada A, Ghaghada KB, Parihar R.
  Sci Adv. 2020 Jul. 28(6).

• Intratumoral CD4⁺ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.

  Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L.
  Cell. 2020 Jun 25. 7(181).
  
  Data Clinical Trial

• MUC1-C drives stemness in progression of colitis to colorectal cancer.

  Li W, Zhang N, Jin C, Long MD, Rajabi H, Yasumizu Y, Fushimi A, Yamashita N, Hagiwara M, Zheng R, Wang J, Kui L, Singh H, Kharbanda S, Hu Q, Liu S, Kufe D.
  JCI Insight. 2020 Jun 18. 12(5).
  
  Data

• Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.

  Fucà G, Reppel L, Landoni E, Savoldo B, Dotti G.
  Clin Cancer Res. 2020 Jun 01. 11(26).

• Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.

  Liu C, Sadat SH, Ebisumoto K, Sakai A, Panuganti BA, Ren S, Goto Y, Haft S, Fukusumi T, Ando M, Saito Y, Guo T, Tamayo P, Yeerna H, Kim W, Hubbard J, Sharabi AB, Gutkind JS, Califano JA.
  Clin Cancer Res. 2020 Jun 01. 11(26).

• ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.

  Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW.
  Cancer Res. 2020 Jun 01. 11(80).

• Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

  Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, Odunsi A.
  J Immunother Cancer. 2020 Jun. 1(8).

• Adoptive T cell therapy: Boosting the immune system to fight cancer.

  Leon E, Ranganathan R, Savoldo B.
  Semin Immunol. 2020 Jun. (49).

• Humoral immune responses: Unsung heroes of the war on cancer.

  Conejo-Garcia JR, Biswas S, Chaurio R.
  Semin Immunol. 2020 Jun. (49).

• IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.

  Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, Alexandrov LB, Koyama Y, Nishio T, Benner C, Heinz S, Rosenthal SB, Liang S, Sun M, Karin G, Zhao P, Brodt P, Mckillop IH, Quehenberger O, Dennis E, Saltiel A, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T.
  J Hepatol. 2020 May. 5(72).

• Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.

  Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L.
  J Immunother Cancer. 2020 May. 1(8).
  
  Clinical Trial

• Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer.

  Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S, Tang DG.
  Nat Commun. 2020 Apr 29. 1(11).
  
  Data

• New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.

  Williams KB, Largaespada DA.
  Genes (Basel). 2020 Apr 28. 5(11).

• Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers.

  Shalapour S, Karin M.
  Annu Rev Immunol. 2020 Apr 26. (38).

• Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.

  Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO.
  Int J Cancer. 2020 Apr 15. 8(146).

• TLR9 Sensing of Self-DNA Controls Cell-Mediated Immunity to Listeria Infection via Rapid Conversion of Conventional CD4⁺ T Cells to T_reg.

  Dolina JS, Lee J, Griswold RQ, Labarta-Bajo L, Kannan S, Greenbaum JA, Bahia El Idrissi N, Pont MJ, Croft M, Schoenberger SP.
  Cell Rep. 2020 Apr 07. 1(31).

• Multi-omics Visualization Platform: An extensible Galaxy plug-in for multi-omics data visualization and exploration.

  McGowan T, Johnson JE, Kumar P, Sajulga R, Mehta S, Jagtap PD, Griffin TJ.
  Gigascience. 2020 Apr 01. 4(9).

• HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING.

  Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL.
  J Clin Invest. 2020 Apr 01. 4(130).

• Immunotherapy of multiple myeloma.

  Minnie SA, Hill GR.
  J Clin Invest. 2020 Apr 01. 4(130).

• Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.

  Brightman SE, Naradikian MS, Miller AM, Schoenberger SP.
  J Leukoc Biol. 2020 Apr. 4(107).

• Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers.

  Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, Hu Q, Liu S, Black DL, Witte ON, Xing Y.
  Proc Natl Acad Sci U S A. 2020 Mar 10. 10(117).
  
  Data

• Immunotherapy, Inflammation and Colorectal Cancer.

  Lichtenstern CR, Ngu RK, Shalapour S, Karin M.
  Cells. 2020 Mar 04. 3(9).

• Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.

  Yang Y, Jain RK, Glenn ST, Xu B, Singh PK, Wei L, Hu Q, Long M, Hutson N, Wang J, Battaglia S, George S.
  J Immunother Cancer. 2020 Mar. 1(8).

• HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.

  Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB.
  Cancer Res. 2020 Feb 15. 4(80).

• Blockade of IL-17 signaling reverses alcohol-induced liver injury and excessive alcohol drinking in mice.

  Xu J, Ma HY, Liu X, Rosenthal S, Baglieri J, McCubbin R, Sun M, Koyama Y, Geoffroy CG, Saijo K, Shang L, Nishio T, Maricic I, Kreifeldt M, Kusumanchi P, Roberts A, Zheng B, Kumar V, Zengler K, Pizzo DP, Hosseini M, Contet C, Glass CK, Liangpunsakul S, Tsukamoto H, Gao B, Karin M, Brenner DA, Koob GF, Kisseleva T.
  JCI Insight. 2020 Feb 13. 3(5).

• CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.

  Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD.
  J Clin Invest. 2020 Feb 03. 2(130).
  
  Data Clinical Trial

• In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma.

  Li F, Huang Q, Luster TA, Hu H, Zhang H, Ng WL, Khodadadi-Jamayran A, Wang W, Chen T, Deng J, Ranieri M, Fang Z, Pyon V, Dowling CM, Bagdatlioglu E, Almonte C, Labbe K, Silver H, Rabin AR, Jani K, Tsirigos A, Papagiannakopoulos T, Hammerman PS, Velcheti V, Freeman GJ, Qi J, Miller G, Wong KK.
  Cancer Discov. 2020 Feb. 2(10).
  
  Data

• Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

  Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L.
  Cancer Immunol Res. 2020 Feb. 2(8).

• Filmed over with CAR-T cells.

  Adu-Berchie K, Mooney DJ.
  Nat Biomed Eng. 2020 Feb. 2(4).

• Orchestrating single-cell analysis with Bioconductor.

  Amezquita RA, Lun ATL, Becht E, Carey VJ, Carpp LN, Geistlinger L, Marini F, Rue-Albrecht K, Risso D, Soneson C, Waldron L, Pagès H, Smith ML, Huber W, Morgan M, Gottardo R, Hicks SC.
  Nat Methods. 2020 Feb. 2(17).

• Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.

  Detappe A, Mathieu C, Jin C, Agius MP, Diringer MC, Tran VL, Pivot X, Lux F, Tillement O, Kufe D, Ghoroghchian PP.
  Int J Radiat Oncol Biol Phys. 2020 Dec 01. 5(108).

• An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.

  Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ.
  Mol Imaging Biol. 2020 Dec. 6(22).

• Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.

  Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L.
  Cancer Immunol Res. 2020 Dec. 12(8).
  
  Data Clinical Trial

• Engineering cytokines and cytokine circuits.

  Li AW, Lim WA.
  Science. 2020 Nov 27. 6520(370).

• Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window.

  Wang X, Wilhelm J, Li W, Li S, Wang Z, Huang G, Wang J, Tang H, Khorsandi S, Sun Z, Evers B, Gao J.
  Nat Commun. 2020 Nov 17. 1(11).

• Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.

  Li S, Bennett ZT, Sumer BD, Gao J.
  Acc Chem Res. 2020 Nov 17. 11(53).

• Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).

  Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, O'Donnell T, Merritt E, Simons NW, Barcessat V, Del Valle DM, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Laserson U, Rahman A, Kim-Schulze S, Charney AW, Gnjatic S, Gelb BD, Merad M, Bogunovic D.
  Cell. 2020 Nov 12. 4(183).
  
  Data

• Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation.

  Becher LRE, Nevala WK, Sutor SL, Abergel M, Hoffmann MM, Parks CA, Pease LR, Schrum AG, Markovic SN, Gil D.
  Blood Adv. 2020 Nov 10. 21(4).

• Fate and functional roles of Prominin 1⁺ cells in liver injury and cancer.

  Wu R, Pan S, Chen Y, Nakano Y, Li M, Balog S, Tsukamoto H.
  Sci Rep. 2020 Nov 10. 1(10).

• Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.

  Wang H, Najibi AJ, Sobral MC, Seo BR, Lee JY, Wu D, Li AW, Verbeke CS, Mooney DJ.
  Nat Commun. 2020 Nov 10. 1(11).

• Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

  Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S.
  Blood Adv. 2020 Nov 10. 21(4).

• Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST.

  Chaney KE, Perrino MR, Kershner LJ, Patel AV, Wu J, Choi K, Rizvi TA, Dombi E, Szabo S, Largaespada DA, Ratner N.
  Cancer Res. 2020 Nov 01. 21(80).

• Immune checkpoint inhibitors to treat cutaneous malignancies.

  Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME.
  J Am Acad Dermatol. 2020 Nov. 5(83).

• Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s.

  Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, Liu S, Ito F.
  Nat Commun. 2020 Oct 27. 1(11).
  
  Data

• Fructose stimulated de novo lipogenesis is promoted by inflammation.

  Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle PJ, Watrous JD, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco MT, Moscat J, Knight R, Greten FR, Lau LF, Metallo CM, Febbraio MA, Karin M.
  Nat Metab. 2020 Oct. 10(2).

• Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model.

  Baniel CC, Sumiec EG, Hank JA, Bates AM, Erbe AK, Pieper AA, Hoefges AG, Patel RB, Rakhmilevich AL, Morris ZS, Sondel PM.
  J Immunother Cancer. 2020 Oct. 2(8).

• An inflammatory cytokine signature predicts COVID-19 severity and survival.

  Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S.
  Nat Med. 2020 Oct. 10(26).
  
  Data

• MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

  Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D.
  Nat Commun. 2020 Jan 17. 1(11).
  
  Data

• CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer.

  Kemnade JO, Elhalawani H, Castro P, Yu J, Lai S, Ittmann M, Mohamed ASR, Lai SY, Fuller CD, Sikora AG, Sandulache VC.
  Sci Rep. 2020 Jan 14. 1(10).

• Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.

  Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E.
  Clin Cancer Res. 2020 Jan 01. 1(26).

• The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.

  Hou J, Zhang H, Sun B, Karin M.
  J Hepatol. 2020 Jan. 1(72).

• Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

  Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.
  Cancer Discov. 2020 Jan. 1(10).
  
  Clinical Trial

• Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.

  Lu T, Tang J, Shrestha B, Heath BR, Hong L, Lei YL, Ljungman M, Neamati N.
  Theranostics. 2020. 15(10).

• Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma.

  Jin WJ, Erbe AK, Schwarz CN, Jaquish AA, Anderson BR, Sriramaneni RN, Jagodinsky JC, Bates AM, Clark PA, Le T, Lan KH, Chen Y, Kim K, Morris ZS.
  Front Immunol. 2020. (11).

• In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response.

  Baniel CC, Heinze CM, Hoefges A, Sumiec EG, Hank JA, Carlson PM, Jin WJ, Patel RB, Sriramaneni RN, Gillies SD, Erbe AK, Schwarz CN, Pieper AA, Rakhmilevich AL, Sondel PM, Morris ZS.
  Front Immunol. 2020. (11).
  
  Clinical Trial

• Exploiting nanoscale cooperativity for precision medicine.

  Wilhelm J, Wang Z, Sumer BD, Gao J.
  Adv Drug Deliv Rev. 2020. (158).

• Log-epsilon-skew normal: A generalization of the log-normal distribution.

  Hutson AD, Mashtare TL, Mudholkar GS.
  Commun Stat Theory Methods. 2020. 17(49).

• Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model.

  Gross NT, Wang J, Fiandalo MV, Cortes Gomez E, Watts A, Godoy AS, Smith GJ, Wu Y.
  PLoS One. 2020. 6(15).

• Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

  Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Lacouture ME.
  Support Care Cancer. 2020 Dec. 12(28).

• Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes.

  Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud JN, Davicioni E, Liu S, Heemers HV.
  Eur Urol Open Sci. 2020 Dec. (22).

• Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.

  Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA.
  Clin Exp Med. 2020 Nov. 4(20).

• Immune checkpoint inhibitor-related dermatologic adverse events.

  Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME.
  J Am Acad Dermatol. 2020 Nov. 5(83).

• Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma.

  Heft Neal ME, Bhangale AD, Birkeland AC, McHugh JB, Shuman AG, Rosko AJ, Swiecicki PL, Spector ME, Brenner JC.
  Cancers (Basel). 2020 Oct 22. 11(12).

• Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

  Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M.
  J Am Acad Dermatol. 2020 Oct. 4(83).

• Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers.

  Takahashi H, Oshi M, Asaoka M, Yan L, Endo I, Takabe K.
  Ann Surg Oncol. 2020 Oct. 11(27).

• PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.

  Saglam O, Zhou J, Wang X, Conejo-Garcia JR.
  Int J Gynecol Pathol. 2020 Sep. 5(39).

• Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis.

  Takahashi H, Katsuta E, Yan L, Tokumaru Y, Katz MHG, Takabe K.
  Cancers (Basel). 2020 Jul 24. 8(12).

• Precursor Intensity-Based Label-Free Quantification Software Tools for Proteomic and Multi-Omic Analysis within the Galaxy Platform.

  Mehta S, Easterly CW, Sajulga R, Millikin RJ, Argentini A, Eguinoa I, Martens L, Shortreed MR, Smith LM, McGowan T, Kumar P, Johnson JE, Griffin TJ, Jagtap PD.
  Proteomes. 2020 Jul 08. 3(8).

• Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.

  Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K.
  Oncotarget. 2020 Jul 07. 27(11).

• Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).

  Gruber C, Patel R, Trachman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, Simons N, Barcessat V, Valle DD, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Rahman A, Kim-Schulze S, Charney A, Gnjatic S, Gelb BD, Merad M, Bogunovic D.
  medRxiv. 2020 Jul 06. ().

• Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments.

  Jagodinsky JC, Morris ZS.
  Semin Radiat Oncol. 2020 Apr. 2(30).

• Stearoyl-CoA desaturase and tumorigenesis.

  Kikuchi K, Tsukamoto H.
  Chem Biol Interact. 2020 Jan 25. (316).

• STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.

  Kim JW, Berrios C, Kim M, Schade AE, Adelmant G, Yeerna H, Damato E, Iniguez AB, Florens L, Washburn MP, Stegmaier K, Gray NS, Tamayo P, Gjoerup O, Marto JA, DeCaprio J, Hahn WC.
  Elife. 2020 Jan 08. (9).